Bavarian Nordic hit by cancer immunotherapy failure

18th September 2017 Uncategorised 0

Bavarian Nordic saw its shares plummet as much as 50 percent in the wake of news that the firm’s cancer immunotherapy ProstVac failed to prolong survival in men with a particular type of prostate cancer.

More: Bavarian Nordic hit by cancer immunotherapy failure
Source: News